Skip to main content
Premium Trial:

Request an Annual Quote

Compugen s Q1 Revenues Jump, Net Losses Narrow

NEW YORK, April 30 - Compugen said Monday its first-quarter net revenues increased to $2.2 million for the quarter, compared with $859,000 in the year-ago period as the Tel Aviv-based company posted growing sales for its proteomics technology and Gencarta database.

“We are very pleased with our financial results as we continue to significantly expand the company's R&D efforts and commercial operations,” Martin Gerstel, chairman of Compugen's board, said in a statement.
 
Notable sources of revenue for the quarter included an agreement with Avalon pharmaceuticals to license the company's newly launched Gencarta transcriptome and proteome database as well as new customers for the company's enhanced Z3 proteomics analysis system.

The company's expenses increased to $7 million in the quarter, compared with $5 million for first-quarter 2000. This included $3.5 million in R&D expenses and $2.5 million in sales, general, and administrative expenses.

Compugen net losses narrowed to $3.6 million, or 14 cents per share, compared to net losses of $4 million, or 63 cents per shared, but failed to meet Wall Street's expectations. According to a poll of two brokers conducted by First Call/Thomson Financial, analysts expected net losses of 13 cents a share.

As of March 31, the company had cash and cash equivalents of $77.8 million, down from $90.7 million in December 31.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.